MiNK Therapeutics, Inc.
INKTNASDAQHealthcare● Active
$11.95
+$0.61(+5.34%)
Market Cap$59508784
P/E Ratio—
52W High$76
52W Low$6.8
MiNK Therapeutics, Inc. (INKT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INKT · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.57
Est. -$0.77 · +26.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
INKT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.60 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.77 | -$0.57 | +26.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 17, 2026 | -$0.68 | -$0.52 | +23.5% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.86 | -$0.65 | +24.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.55 | -$1.06 | -92.7% | — | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.61 | -$0.70 | -14.8% | — | — | — |
| ▼ Q1 FY2025 | Mar 18, 2025 | -$0.50 | -$0.62 | -24.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.80 | -$0.50 | +37.5% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.57
EPS Est.
-$0.77
EPS Surpr.
+26.0%
Revenue
—
Q1 FY2026
Mar 17, 2026Beat
EPS Actual
-$0.52
EPS Est.
-$0.68
EPS Surpr.
+23.5%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.65
EPS Est.
-$0.86
EPS Surpr.
+24.4%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$1.06
EPS Est.
-$0.55
EPS Surpr.
-92.7%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.70
EPS Est.
-$0.61
EPS Surpr.
-14.8%
Revenue
—
Q1 FY2025
Mar 18, 2025Miss
EPS Actual
-$0.62
EPS Est.
-$0.50
EPS Surpr.
-24.0%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.50
EPS Est.
-$0.80
EPS Surpr.
+37.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.15 | $-1.15 | $-1.15 | 1 |
| Q3 FY2027 | $-1.14 | $-1.14 | $-1.14 | 1 |
| Q2 FY2027 | $-1.13 | $-1.13 | $-1.13 | 1 |
| Q1 FY2027 | $-1.13 | $-1.13 | $-1.13 | 1 |
| Q4 FY2026 | $-0.66 | $-0.66 | $-0.66 | 1 |
| Q3 FY2026 | $-0.63 | $-0.63 | $-0.63 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +26.0% | $10.51 | $10.72 | +2.00% |
| ▲ Q1 FY2026 | Mar 17, 2026 | +23.5% | $9.12 | $9.57 | +4.93% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +24.4% | $13.22 | $12.75 | -3.56% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -92.7% | $17.50 | $15.32 | -12.46% |
| ▼ Q2 FY2025 | May 15, 2025 | -14.8% | $7.50 | $7.18 | -4.27% |
| ▼ Q1 FY2025 | Mar 18, 2025 | -24.0% | $8.52 | $8.24 | -3.29% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +37.5% | $7.94 | $7.50 | -5.54% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +30.0% | $8.35 | $8.49 | +1.68% |
Q2 FY2026+2.00%
Report Date
May 15, 2026
EPS Beat/Miss
+26.0%
Price Before
$10.51
Price After
$10.72
Q1 FY2026+4.93%
Report Date
Mar 17, 2026
EPS Beat/Miss
+23.5%
Price Before
$9.12
Price After
$9.57
Q4 FY2025-3.56%
Report Date
Nov 14, 2025
EPS Beat/Miss
+24.4%
Price Before
$13.22
Price After
$12.75
Q3 FY2025-12.46%
Report Date
Aug 14, 2025
EPS Beat/Miss
-92.7%
Price Before
$17.50
Price After
$15.32
Q2 FY2025-4.27%
Report Date
May 15, 2025
EPS Beat/Miss
-14.8%
Price Before
$7.50
Price After
$7.18
Q1 FY2025-3.29%
Report Date
Mar 18, 2025
EPS Beat/Miss
-24.0%
Price Before
$8.52
Price After
$8.24
Q4 FY2024-5.54%
Report Date
Nov 14, 2024
EPS Beat/Miss
+37.5%
Price Before
$7.94
Price After
$7.50
Q3 FY2024+1.68%
Report Date
Aug 13, 2024
EPS Beat/Miss
+30.0%
Price Before
$8.35
Price After
$8.49
Avg Beat Reaction-0.10%
Avg Miss Reaction-6.67%
Beat Rate5 / 8 quarters
Largest Move-12.46% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INKT ends December
MiNK Therapeutics, Inc. (INKT) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.57 — beating the analyst consensus of $-0.77 by +26.0%. INKT has beaten EPS estimates for 3 consecutive quarters. The next INKT earnings date is expected around September 1, 2026.
Each quarter, investors track INKT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INKT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INKT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INKT earnings · 5 questionsMiNK Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. INKT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INKT historically reports after market close (AMC).
INKT earnings datewhen is INKT earningsINKT next earnings datewhen does INKT report earningsINKT earnings calendar
▸ Source: FMP · MiNK Therapeutics, Inc. SEC filings · US GAAP · MiNK Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026